Retrogenix, a Charles River Company provides a fast, accurate, and effective solution for primary receptor identification and specificity screening of antibodies, protein ligands, CAR T cells, and other biotherapeutics. Biologically relevant targets are identified by screening for interactions against the most comprehensive set of the plasma membrane and tethered secreted proteins that are expressed in
human cells. This informs lead selection, assists with safety assessment, and has generated data that has been used in patent applications and NDA submissions to both the US FDA and EMA.
For more details of our technology see our website animation at:Â www.retrogenix.com/the-technology/